Company advances regulatory submissions for diagnostic products while reporting a significant decline in cash reserves.
Co-Diagnostics submitted dual 510(k) and CLIA waiver applications to the FDA, marking a key step toward commercializing its diagnostic platform. The move comes as the company’s cash balance fell to $3.6 million in Q2 2026, raising liquidity concerns.
Management described the quarter as pivotal for transitioning from development to commercialization, citing expanded global opportunities and enhanced platform capabilities. Prior quarters focused on R&D, with regulatory filings now accelerating.
No immediate market reaction was disclosed, though the cash decline may weigh on investor sentiment amid ongoing commercialization efforts.